This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Skin Cancer  • Dermatology  • Dermatologic Disorders  • Neoplasms  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Urs V. Buettiker, MD; Nikhil Y. Yawalkar, MD; Lasse R. Braathen, MD, PhD, MHA; Robert E. Hunger, MD, PhD

Arch Dermatol. 2008;144(7):943-945.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Lentigo maligna (LM) is an in situ lesion with a 2% to 50% risk of progression to LM melanoma.¹ Currently, surgery or radiotherapy is usually recommended as the primary treatment for LM. In the literature, the recurrence rates reported for radiotherapy range from 0% to 19%, with a mean recurrence rate of approximately 7%; in addition, radiotherapy carries the risk of causing chronic radiodermatitis or radiation-induced malignant neoplasm.² A margin-controlled excision using "slow Mohs" (rush permanent sections) and Mohs micrographic surgery has the lowest recurrence rate, perhaps as low as 3%.³

Methods

Thirty-two patients with 34 histologically confirmed facial LM lesions were enrolled in an open-label trial of imiquimod, 5%, cream (Aldara; 3M Pharma, Rueschlikon, Switzerland). No patient had been treated by other methods previously. The diagnosis was based on clinical examination . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?